Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA

Full Text:

Abstract

to assess the effectiveness of medicines the retrospective observational study of 1343 case of hospitalization (case reports) of 214 colorectal cancer patients treated with oxaliplatin at the St. Petersburg State Health Care Institution «City Clinical Oncology Dispensary» in 2008-2010 was done. Pharmacoeconomic analysis of application of oxaliplatin in colorectal cancer was performed. Cost-effectiveness analysis was used. Calculation of direct medical costs, direct non-medical costs and indirect costs was performed. Three trade names of oxaliplatin was used: eloxatin – 42.2%; platikad – 31.6%; eksorum – 26.2%. Middle cover price of case report
was 252,294 rubles. In average oxaliplatin therapy was effective in 83.1%. ICER for eloxatin was 8,801 and 18,162 compared to eksorum and platikad respectively. As a result it was shown that the treatment with eloxatin was clinical and cost-effective.

About the Authors

A. V. Pavlysh
The first St. Petersburg State Medical University named after Academician Pavlov
Russian Federation


A. S. Kolbin
The first St. Petersburg State Medical University named after Academician Pavlov; Saint Petersburg State University
Russian Federation


A. R. Kasimova
The first St. Petersburg State Medical University named after Academician Pavlov
Russian Federation


References

1. Belousov Yu.B. Planning and conduct of clinical trials of medicinal products [Planirovanie i provedenie klinicheskikh issledovanii lekarstvennykh sredstv]. Moscow. 2000; 579 s.

2. Gan'shina I.P., Barsukov Yu.A. Vestnik RONTs im. N.N. Blokhina RAMN. 2006; 17 (3): 5-11.

3. Data on the purchase of the St. Petersburg government health care «City Clinical Oncology Dispensary» [Dannye zakupki Sankt-Peterburgskogo gosudarstvennogo uchrezhdeniya zdravookhraneniya «Gorodskoi klinicheskii onkologicheskii dispanser»]. 2010.

4. Kaprin A.D., Starinskii V.V., Petrova G.V. Malignancies in 2012 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v 2012 godu (zabolevaemost' i smertnost')]. Moscow. 2013.

5. The Ministry of Health of the Russian Federation. №163 order dated 27.05.2011. Industry standard clinical and economic research. General provisions 91500.14.0001-2002. [Ministerstvo Zdravookhraneniya Rossiiskoi Federatsii. Prikaz №163 ot 27.05.2011. Otraslevoi standart kliniko-ekonomicheskogo issledovaniya. Obshchie polozheniya 91500.14.0001-2002].

6. Yagudina R.I., Kulikov A.Yu., Nguen T. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2011; 4 (1): 7-12.

7. Gold M., Siegel J.E., Russell L.B., Weinstein M.C. Costeffectiveness in Health and Medicine. New York. 1996. 425 s.

8. http://www.gks.ru

9. Walley T., Haycox A., Boland A. Pharmacoeconomics – Elsevier Health Sciences. 2004. 216 s.


For citation:


Pavlysh A.V., Kolbin A.S., Kasimova A.R. PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(3):26-29. (In Russ.)

Views: 300


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)